Thomas T.H. Chou

Thomas T.H. Chou


University of California, Los Angeles (B.A., 1995)
Lewis & Clark Law School (J.D., 1998)

Bar Admissions


Thomas Chou is a partner and co-head of the firm’s Asia Private Equity practice and a leader in the firm’s China M&A practice, both of which are consistently highly ranked in major independent industry league tables and lawyer ranking organizations — including a #1 ranking (Asia Pacific M&A – private equity deal value) in Bloomberg’s 2017 M&A league tables.

Mr. Chou has an active corporate practice, focusing on cross-border mergers and acquisitions (inbound and outbound), joint ventures and private equity and venture capital financings. His clients include emerging growth companies, as well as traditional and non-traditional investors (private equity and venture capital funds, corporate/strategic investment arms of corporations, financial institutions, insurance companies and sovereign wealth funds). His practice is focused on the technology, media and telecom, healthcare and life sciences and consumer and retail industries.

Mr. Chou is also consistently recognized as a leading individual lawyer in the areas of M&A, private equity and venture capital and TMT by major independent lawyer ranking organizations, including Chambers Global, Chambers Asia Pacific, Legal 500 Asia Pacific and IFLR1000. His most recent individual rankings include being listed as a leading individual in China for Private Equity (Buyouts) and Corporate/M&A by Chambers Asia Pacific 2019 and being recommended for China Corporate and M&A: Foreign Firms, China Fintech: Foreign Firms, China TMT: Foreign Firms, China Private Equity / Venture Capital: Foreign Firms, Hong Kong Corporate (including M&A), Hong Kong Private Equity and Hong Kong TMT  by Legal 500 Asia Pacific 2019.

Chambers Asia Pacific 2019 notes that "he commands considerable respect from private equity clients" and quotes clients saying that "he is patient, attentive to details and someone who has clearly conquered many battlefields."

Chambers Asia Pacific 2017 notes that he “can stand his ground and be very strong without being inflammatory.”

He is also praised for his negotiation skills, and that "he is just generally a good deal-maker."

Representative Matters:

  • Represented SoftBank in its US$9.6 billion investment in Xiaoju Kuaizhi Inc. (DiDi), China’s leading ride-hailing and mobile transportation platform.
  • Represented Ally Bridge Group in its equity investment in GRAIL, Inc., a company developing a blood test to detect cancer early before symptoms appear in order to offer higher survival rates compared to late-stage diagnosis. The investment, led by Ally Bridge Group, raised US$300 million in an oversubscribed Series C financing.
  • Represented one of the Asian private equity investors in a Series B plus financing totaling US$35 million in Hangzhou Just Biotherapeutics (HJB), HJB is a biopharmaceutical company that develops antibody and recombinant protein biotherapeutics in China.
  • Represented NewQuest Capital Partners in its secondary acquisition of shares in three portfolio companies from a prominent corporate venture capital firm.

SoftBank’s $9.6 billion investment in DiDi.
Represented SoftBank in its $9.6 billion investment in Xiaoju Kuaizhi Inc. (DiDi), China’s leading ride-hailing and mobile transportation platform. 

Airbnb’s China Market Entry
Representing Airbnb on its China market entry.

Kirin Holdings’ Investment in Brooklyn Brewing
Representing Kirin Holdings Company, a leading Japanese company in the global food and beverage market, in its equity investment for a 24.5% stake Brooklyn Brewing Corporation, a craft beer manufacturer in Brooklyn, New York.

Xingren’s Financing Led by FountainVest
Representing Xingren, a Shanghai-based healthcare mobile app maker, in its US$32 million (RMB200 million) series B round of financing led by FountainVest Partners with participation of existing investors Sequoia China and Lightspeed China. The app allows Chinese doctors and patients to interact. It also serves as a social networking platform and online knowledge center for doctors.

The Void’s Strategic Transaction with Shanda
Representing The Void, LLC, a Utah-based developer of virtual reality theme park technology,  in a strategic transaction with the Singapore and Shanghai-based Shanda Group.  The Void is commercializing a one-of-a-kind entertainment offering that allows a gamer to roam freely within and interact with a purpose-built set while wearing a VR headset, gloves and a vest for interaction and haptic feedback. (2016)

ClearVue’s Investment in CHIC Fresh
Represented ClearVue Partners in a debt and minority equity investment in CHIC Fresh, a High Pressure Processing (HPP) juice and beverage company with operations in Asia, Europe and North America. (2016)

New China Capital’s Funding for Xin Wing
Represented New China Capital Management L.P. in its participation in a RMB1.3 billion (US$200 million) round of funding for Xin Wing Enterprises Limited. Xin Wing Enterprises Limited owns Fujian Sunreal Pro-Environmental Wallpaper Co., Ltd., which is an established wallpaper and other paper related products manufacturer in Zhangzhou, Fujian of the PRC. (2016)

Ally Bridge’s Investments in the Life Sciences Sector
Represented Ally Bridge Group in connection with its investments in various life sciences companies, including 1) its participation of US$155 million private placement of shares in Boston-based oncology-focused biopharmaceutical company TESARO, Inc.; 2) US$38 million Series B preferred round of funding into Delaware-based Lithoplasty technology firm ShockWave Medical, Inc.; and 3) US$57 million series E preferred round of funding for US-based endoscopic imaging specialist EndoChoice.

Contineo’s General Corporate Counsel
Act as general corporate counsel to Contineo Limited and advising the company in relation to corporate finance matters. Based in Hong Kong, Contineo operates a messaging network for equity-linked structured products with Barclays, BNP Paribas, BSI, Goldman Sachs, HSBC, JP Morgan, Julius Baer, Natixis and Societe Generale as subscribers.

Particle Inc.’s Series D Financing
Represented Particle Inc., a leading media company that provides an intelligent news aggregator mobile application in China in its Series D financing with leading private equity investors and Chinese mobile handset companies. (2016)

Spacious’ Financing
Represented Spacious, an Asian online residential real estate marketplace, in its convertible note and Series A financing. (2015)

Lamplight Analytics’ Investment Led by Vectr Ventures
Represented Lamplight Analytics, an Asia social data analytics company, in its convertible note investment lead by Vectr Ventures. (2015)

Arocrest Capital’s Investment in TruTag
Represented Arocrest Capital Management in its Series B investment in TruTag Technologies, Inc., a provider of custom product authentication and brand protection solutions. (2015)

GREE in HotelQuickly’s Financing
Represented GREE, Inc. in connection with HotelQuickly Holding’s Series A-1 equity financing. HotelQuickly is an Asia-Pacific-based technology firm enabling users throughout Asia to make last-minute hotel room bookings at deeply discounted prices via mobile app. GREE was the lead investor in the Series A-1 round, and was joined by the founder and chairman of Minor International, a Thailand based conglomerate in the hospitality space. (2014)

JimuBox’s Financing
Represented JimuBox, a Beijing-based peer-to-peer (P2P) online lending platform, in its initial round of external financing. (2014)

NewQuest’s Sale of Shares in iKang
Represented NewQuest Asia Investments Limited in its sale of preferred shares in iKang Healthcare Group, a Beijing-based Chinese healthcare services provider, to a Hong Kong-based hedge fund focused on mainland PRC equities. iKang Healthcare provides preventive healthcare solutions including medical examination services, disease screening and other services in the fast growing China market. (2014)

Intel Capital and Northern Light’s Investment into Zamplus Technology
Represented Intel Capital and Northern Light Venture Capital in a US$15 million preferred equity investment into Zamplus Technology, a Chinese provider of search engine marketing solutions and operator of demand side platform and ad exchange platform. (2013)

Domain Partners
Advised Domain Partners, a life sciences venture firm based in San Diego and Princeton in connection with a joint venture with Beijing-based firm Elite Consulting to localize and commercialize various healthcare-related technologies in China. (2013)

Innovata and Tianjin KingYork Joint Venture
Advised on a transforming and complex joint venture (JV) arrangement between Innovata BioMed, part of the Vectura Group, and Innovata HK Ltd., a Hong Kong-based entity, which has formed a significant mainland China JV with its JV partner Tianjin KingYork Group Co. Ltd., one of the leading pharmaceutical companies in China. (2013)

Aspect Gaming
Advised Macau and Shanghai based Aspect Gaming, a supplier of Asian clientele-focused casino gaming content, in its acquisition of Longshot Interactive, a Las Vegas based casino games developer focused on creating Asian-clientele targeted casino games, including a number of proprietary baccarat variants. (2013)

Kirin Holdings' Beverage Joint Venture with China Resources Enterprise
Advising Kirin Holdings, a leading Japanese company in the global food and beverage market, in its US$400 million strategic joint venture with China Resources Enterprise, a Hong Kong-based consumer goods company operating in the retail, beer, food and beverage markets throughout China. (2011)

Rakuten's Joint Venture with Baidu, Inc.
Advised Rakuten with respect to its joint venture with Baidu, Inc., the leading Chinese language Internet service provider, to build a online shopping mall for Chinese Internet users. (2010)

Harbin Pharmaceutical’s Landmark Acquisition of Pfizer Business in China
Advised one of the largest pharmaceutical companies in China, Harbin Pharmaceutical, in its asset acquisition of Pfizer’s swine vaccine business in China. This is the first MOFCOM-ordered divestment of its kind. Financial Times refers to this transaction as a "watershed Chinese deal…the first of many such transfers of western IP to Chinese groups arising from local competition rulings." (2010)

Mount Kellett Capital
Represented Mount Kellett Capital in an undisclosed investment in Asia. (2010)

Eddingpharm’s Series B Financing
Advised OrbiMed Advisors and Domain Associates in the initial closing of a US$24 million Series B Preferred Shares financing of Eddingpharm (Cayman) Inc., a leading pharmaceuticals marketing company in China. (2010)

6 Waves Inc.’s Financing
Represented 6 Waves Inc., a leading global developer of entertainment applications and online social games distributor based on Hong Kong, in a corporate restructuring followed by a US$17.5 million Series A Preferred Shares financing from Insight Venture Partners. (2009)

Carlyle's Investment in iTour International Holdings
Represented Carlyle Asia Growth and other investors in connection with the acquisition of secured convertible notes issued by iTour International Holdings Ltd., one of the leading online travel reservation companies in China. (2009)

Norwest Venture Partners
Represented a global venture and growth equity investment firm in connection with both its Series A Ordinary Shares financing and follow-on investment in a fabless application-specific integrated circuit (ASIC) company with operations in Shanghai, China. (2009)

Ku6 Holding Limited
Represented Draper Fisher Jurvetson and other investors in connection with the sale of their Preferred Shares in Ku6 Holding Limited, a leading online video portal in China, to NASDAQ-listed Hurray! Holding Company Limited. (2009)

Investment Bank's Creation of Special Purpose Financing Vehicle
Represented a major international investment banking firm's private equity arm in an investment in a Hong Kong special purpose vehicle, which in turn acquired certain Philippine and other offshore entities which own and operate a polypropylene plant in the Philippines. (2008)

Merrill Lynch Investment in China Solar Semiconductor Facilities
Represented Merrill Lynch as an arranger of a secured financing facility for an affiliate of a NYSE-listed semiconductor company to fund procurement of thin-film solar semiconductor equipment.

Mr. Chou was ranked as a leading individual for Private Equity (Buyouts) and Corporate/M&A in China by Chambers Asia-Pacific 2019. He was also recommended for China Corporate and M&A: Foreign Firms, China Fintech: Foreign Firms, China TMT: Foreign Firms, China Private Equity / Venture Capital: Foreign Firms, Hong Kong Corporate (including M&A), Hong Kong Private Equity and Hong Kong TMT by Legal 500 Asia-Pacific 2019. IFLR1000 2017 has also recognized him as a leading individual in Hong Kong for Private Equity and M&A.

MoFo ScaleUp

Email Disclaimer

Unsolicited e-mails and information sent to Morrison & Foerster will not be considered confidential, may be disclosed to others pursuant to our Privacy Policy, may not receive a response, and do not create an attorney-client relationship with Morrison & Foerster. If you are not already a client of Morrison & Foerster, do not include any confidential information in this message. Also, please note that our attorneys do not seek to practice law in any jurisdiction in which they are not properly authorized to do so.

©1996-2019 Morrison & Foerster LLP. All rights reserved.